Holen Sie sich die Stockscreener-App
18.36
2.36%
0.4231
Schlusskurs vom Vortag:
$17.94
Offen:
$18.27
24-Stunden-Volumen:
68,374
Relative Volume:
0.60
Marktkapitalisierung:
$160.65M
Einnahmen:
$123.24M
Nettoeinkommen (Verlust:
$136.00K
KGV:
-918.15
EPS:
-0.02
Netto-Cashflow:
$-148.99M
1W Leistung:
+8.92%
1M Leistung:
+32.59%
6M Leistung:
+14.27%
1J Leistung:
+5.03%
1-Tages-Spanne:
$17.57
$18.85
1-Wochen-Bereich:
$15.79
$18.85
52-Wochen-Spanne:
$6.53
$26.40
Seres Therapeutics Inc Stock (MCRB) Company Profile
Firmenname
Seres Therapeutics Inc
Sektor
Branche
Telefon
617 945 9626
Adresse
200 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie MCRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
18.35 | 154.87M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.57 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.66 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.44 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.97 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
311.62 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-08 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-21 | Eingeleitet | JP Morgan | Neutral |
| 2021-07-23 | Herabstufung | Goldman | Neutral → Sell |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-03-05 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-11 | Hochstufung | Jefferies | Hold → Buy |
| 2019-04-30 | Eingeleitet | Jefferies | Hold |
| 2018-10-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-08-04 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-01 | Bestätigt | FBR & Co. | Outperform |
| 2016-08-12 | Bestätigt | FBR Capital | Outperform |
| 2016-08-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Bestätigt | H.C. Wainwright | Buy |
| 2016-07-29 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-03-30 | Eingeleitet | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | Guggenheim | Buy |
| 2016-01-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-10-22 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-07-21 | Eingeleitet | Goldman | Neutral |
| 2015-07-21 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Seres Therapeutics Inc Aktie (MCRB) Neueste Nachrichten
Custom strategy builders for tracking Seres Therapeutics Inc.Market Trend Review & Precise Buy Zone Tips - Newser
Statistical indicators supporting Seres Therapeutics Inc.’s strengthCEO Change & Stock Market Timing Techniques - Newser
Using fundamentals and technicals on Seres Therapeutics Inc.July 2025 Market Mood & Weekly Setup with High ROI Potential - Newser
Published on: 2025-08-19 05:10:31 - Newser
Seres Therapeutics Inc. stock momentum explainedJuly 2025 Sector Moves & Real-Time Chart Pattern Alerts - Newser
Earnings visualization tools for Seres Therapeutics Inc.Weekly Trend Report & Fast Entry High Yield Tips - Newser
How to integrate Seres Therapeutics Inc. into portfolio analysis toolsJuly 2025 Pullbacks & Capital Efficient Trade Techniques - Newser
How to track smart money flows in Seres Therapeutics Inc.Trade Analysis Summary & Scalable Portfolio Growth Ideas - Newser
Should you wait for a breakout in Seres Therapeutics Inc.2025 Analyst Calls & Trade Opportunity Analysis Reports - Newser
Is it time to cut losses on Seres Therapeutics Inc.Quarterly Profit Report & Risk Managed Investment Strategies - Newser
Historical volatility pattern of Seres Therapeutics Inc. visualizedBond Market & AI Forecasted Entry and Exit Points - Newser
Competitive Positioning of Seres Therapeutics Inc.: Is It Leading or LaggingTrade Analysis Summary & Short-Term Trading Alerts - Newser
Using data models to predict Seres Therapeutics Inc. stock movementEarnings Overview Report & Stock Market Timing Techniques - Newser
Risk adjusted return profile for Seres Therapeutics Inc. analyzedQuarterly Portfolio Report & Breakout Confirmation Trade Signals - Newser
Has Seres Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewJuly 2025 Big Picture & AI Enhanced Trading Alerts - Newser
Order flow analysis tools used on Seres Therapeutics Inc.2025 EndofYear Setup & Risk Adjusted Swing Trade Ideas - Newser
Seres (MCRB) Q2 Loss Narrows 34% - AOL.com
Seres Therapeutics Inc. Stock Performance After Earnings: Historical InsightsRisk Management & Weekly Watchlist for Consistent Profits - Newser
What moving averages say about Seres Therapeutics Inc.July 2025 Recap & Fast Entry Momentum Alerts - Newser
Published on: 2025-08-15 16:23:19 - Newser
Is Seres Therapeutics Inc. showing signs of accumulation2025 Market Sentiment & Risk Adjusted Buy and Sell Alerts - Newser
How does Seres Therapeutics Inc. score in quality rankingsEarnings Overview Summary & Fast Moving Stock Trade Plans - mustnews.co.kr
Institutional Tools Highlight Unusual Flow in Seres Therapeutics Inc.2025 Top Decliners & Accurate Entry/Exit Alerts - thegnnews.com
Should you avoid Seres Therapeutics Inc. stock right nowJuly 2025 Highlights & Long-Term Safe Investment Ideas - sundaytimes.kr
Why Seres Therapeutics Inc. stock attracts strong analyst attention2025 AllTime Highs & Daily Volume Surge Signals - Newser
Seres Therapeutics Inc. Bounces Off Moving Average SupportReal Trader Watchlist of Hot Stocks Released - metal.it
Seres Therapeutics Reports Q2 2025 Financial Results - The Globe and Mail
Seres Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Seres Therapeutics shares fall 1.90% after-hours following Q2 2025 earnings call. - AInvest
Promising Developments and Strategic Partnerships Drive Buy Rating for Seres Therapeutics - TipRanks
Seres Therapeutics outlines global Phase II SER-155 trial with 248-patient enrollment amid partnership talks - MSN
Seres Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Seres Therapeutics: Unpacking Strategic Contradictions in Partnerships and FDA Engagements - AInvest
Seres Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:MCRB) - Seeking Alpha
Transcript : Seres Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Sana Biotechnology shares fall 14.12% after-hours following Seres Therapeutics' board changes and clinical advancement updates. - AInvest
Seres Therapeutics, Inc. SEC 10-Q Report - TradingView
Earnings call transcript: Seres Therapeutics reports larger-than-expected Q2 loss - Investing.com Canada
Seres Therapeutics quarterly loss per share $2.27 - MarketScreener
Seres Therapeutics August 2025 slides: SER-155 shows 77% infection reduction - Investing.com
Nxera debuts an obesity pipeline; BridgeBio battles Alynam for market share - Yahoo Finance
Seres Therapeutics: A High-Conviction Biotech Buy Amid Clinical and Strategic Momentum - AInvest
Seres Therapeutics Reports Second Quarter 2025 Financial Results - GuruFocus
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance
Seres Therapeutics Inc. Stock Analysis and ForecastAchieve consistent profits with proven methods - Jammu Links News
Is Seres Therapeutics Inc. a growth stock or a value stockRapid portfolio appreciation - Jammu Links News
Finanzdaten der Seres Therapeutics Inc-Aktie (MCRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Seres Therapeutics Inc-Aktie (MCRB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DesRosier Thomas | See Remarks |
Aug 18 '25 |
Sale |
16.65 |
76 |
1,265 |
7,455 |
| Henn Matthew R | See Remarks |
Aug 18 '25 |
Sale |
16.65 |
73 |
1,215 |
4,548 |
| Young Teresa L. | See Remarks |
Aug 18 '25 |
Sale |
16.65 |
59 |
982 |
5,215 |
| Young Teresa L. | See Remarks |
May 16 '25 |
Sale |
7.28 |
63 |
459 |
5,044 |
| Shaff Eric D. | CEO and President |
May 16 '25 |
Sale |
7.28 |
220 |
1,602 |
10,102 |
| DesRosier Thomas | Chief Legal Officer and EVP |
May 15 '25 |
Sale |
7.28 |
79 |
575 |
7,287 |
| Henn Matthew R | See Remarks |
May 16 '25 |
Sale |
7.28 |
77 |
561 |
4,383 |
| Young Teresa L. | See Remarks |
Feb 18 '25 |
Sale |
0.81 |
3,338 |
2,704 |
97,536 |
| Henn Matthew R. | See Remarks |
Feb 18 '25 |
Sale |
0.81 |
3,953 |
3,204 |
84,443 |
| Shaff Eric D. | CEO and President |
Feb 18 '25 |
Sale |
0.81 |
12,726 |
10,314 |
192,039 |
1.18%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):